Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne

Frank Wang, Heh Shin R Kwak, Nada Elbuluk, Anya L. Kaczmarek, Ted Hamilton, John J. Voorhees, Gary J. Fisher, Sewon Kang

Research output: Contribution to journalArticle

Abstract

Background: The cytochrome P450 (CYP) enzyme CYP26 (retinoic acid [RA] 4-hydroxylase) initiates the catabolism of all-trans RA (tRA) and limits the effects of tRA. The CYP26 enzyme acts specifically on tRA, but not 13-cis RA (isotretinoin), a retinoid used to treat severe acne. However, 13-cis RA can isomerize to tRA, which can then be metabolized by CYP26. Objective: In healthy individuals, we assessed the variability of CYP26 enzymatic activity. We then investigated whether response to oral 13-cis RA among patients with acne correlates with variability in CYP26 expression. Methods: In healthy individuals, we isolated microsomal fractions from the epidermis of keratome biopsy specimens and measured CYP26 enzymatic activity in untreated skin and skin treated with tRA. Enzymatic activity was determined based on rate of formation of 4-hydroxy RA (pg/min/mg microsomal protein). Using real-time polymerase chain reaction we quantified CYP26 messenger RNA induction after tRA application in patients with acne who responded or did not respond to one course of 13-cis RA. Results: In normal-appearing skin (N = 118), CYP26 enzymatic activity was widely variable (1-180 pg/min/mg microsomal fraction; mean 42.7 ± 3.5). Furthermore, CYP26 enzymatic activity was inducible in a dose-dependent manner in normal-appearing skin after tRA application, but not correlated with age or sex (N = 29). In patients with acne, CYP26 messenger RNA induction after 0.1% tRA application did not differ (P > .05) between patients who responded (N = 8, 587 ± 325-fold) or did not respond (N = 8, 657 ± 227-fold) to one course of 13-cis RA. Limitations: The small number of patients with acne treated with 13-cis RA was a major limitation. Conclusion: Factors other than CYP26 activity may determine response to isotretinoin in acne.

Original languageEnglish (US)
Pages (from-to)252-258
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume61
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

Isotretinoin
Acne Vulgaris
Skin
Tretinoin
Cytochrome P-450 Enzyme System
Messenger RNA
Hydroxy Acids
Retinoic Acid 4-Hydroxylase
Retinoids
Epidermis
Real-Time Polymerase Chain Reaction
Biopsy

Keywords

  • cytochrome
  • isotretinoin
  • retinoic acid 4-hydroxylase

ASJC Scopus subject areas

  • Dermatology

Cite this

Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne. / Wang, Frank; Kwak, Heh Shin R; Elbuluk, Nada; Kaczmarek, Anya L.; Hamilton, Ted; Voorhees, John J.; Fisher, Gary J.; Kang, Sewon.

In: Journal of the American Academy of Dermatology, Vol. 61, No. 2, 08.2009, p. 252-258.

Research output: Contribution to journalArticle

Wang, Frank ; Kwak, Heh Shin R ; Elbuluk, Nada ; Kaczmarek, Anya L. ; Hamilton, Ted ; Voorhees, John J. ; Fisher, Gary J. ; Kang, Sewon. / Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne. In: Journal of the American Academy of Dermatology. 2009 ; Vol. 61, No. 2. pp. 252-258.
@article{730bb8ec71b84d07bbd48932fd2a134a,
title = "Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne",
abstract = "Background: The cytochrome P450 (CYP) enzyme CYP26 (retinoic acid [RA] 4-hydroxylase) initiates the catabolism of all-trans RA (tRA) and limits the effects of tRA. The CYP26 enzyme acts specifically on tRA, but not 13-cis RA (isotretinoin), a retinoid used to treat severe acne. However, 13-cis RA can isomerize to tRA, which can then be metabolized by CYP26. Objective: In healthy individuals, we assessed the variability of CYP26 enzymatic activity. We then investigated whether response to oral 13-cis RA among patients with acne correlates with variability in CYP26 expression. Methods: In healthy individuals, we isolated microsomal fractions from the epidermis of keratome biopsy specimens and measured CYP26 enzymatic activity in untreated skin and skin treated with tRA. Enzymatic activity was determined based on rate of formation of 4-hydroxy RA (pg/min/mg microsomal protein). Using real-time polymerase chain reaction we quantified CYP26 messenger RNA induction after tRA application in patients with acne who responded or did not respond to one course of 13-cis RA. Results: In normal-appearing skin (N = 118), CYP26 enzymatic activity was widely variable (1-180 pg/min/mg microsomal fraction; mean 42.7 ± 3.5). Furthermore, CYP26 enzymatic activity was inducible in a dose-dependent manner in normal-appearing skin after tRA application, but not correlated with age or sex (N = 29). In patients with acne, CYP26 messenger RNA induction after 0.1{\%} tRA application did not differ (P > .05) between patients who responded (N = 8, 587 ± 325-fold) or did not respond (N = 8, 657 ± 227-fold) to one course of 13-cis RA. Limitations: The small number of patients with acne treated with 13-cis RA was a major limitation. Conclusion: Factors other than CYP26 activity may determine response to isotretinoin in acne.",
keywords = "cytochrome, isotretinoin, retinoic acid 4-hydroxylase",
author = "Frank Wang and Kwak, {Heh Shin R} and Nada Elbuluk and Kaczmarek, {Anya L.} and Ted Hamilton and Voorhees, {John J.} and Fisher, {Gary J.} and Sewon Kang",
year = "2009",
month = "8",
doi = "10.1016/j.jaad.2009.03.013",
language = "English (US)",
volume = "61",
pages = "252--258",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne

AU - Wang, Frank

AU - Kwak, Heh Shin R

AU - Elbuluk, Nada

AU - Kaczmarek, Anya L.

AU - Hamilton, Ted

AU - Voorhees, John J.

AU - Fisher, Gary J.

AU - Kang, Sewon

PY - 2009/8

Y1 - 2009/8

N2 - Background: The cytochrome P450 (CYP) enzyme CYP26 (retinoic acid [RA] 4-hydroxylase) initiates the catabolism of all-trans RA (tRA) and limits the effects of tRA. The CYP26 enzyme acts specifically on tRA, but not 13-cis RA (isotretinoin), a retinoid used to treat severe acne. However, 13-cis RA can isomerize to tRA, which can then be metabolized by CYP26. Objective: In healthy individuals, we assessed the variability of CYP26 enzymatic activity. We then investigated whether response to oral 13-cis RA among patients with acne correlates with variability in CYP26 expression. Methods: In healthy individuals, we isolated microsomal fractions from the epidermis of keratome biopsy specimens and measured CYP26 enzymatic activity in untreated skin and skin treated with tRA. Enzymatic activity was determined based on rate of formation of 4-hydroxy RA (pg/min/mg microsomal protein). Using real-time polymerase chain reaction we quantified CYP26 messenger RNA induction after tRA application in patients with acne who responded or did not respond to one course of 13-cis RA. Results: In normal-appearing skin (N = 118), CYP26 enzymatic activity was widely variable (1-180 pg/min/mg microsomal fraction; mean 42.7 ± 3.5). Furthermore, CYP26 enzymatic activity was inducible in a dose-dependent manner in normal-appearing skin after tRA application, but not correlated with age or sex (N = 29). In patients with acne, CYP26 messenger RNA induction after 0.1% tRA application did not differ (P > .05) between patients who responded (N = 8, 587 ± 325-fold) or did not respond (N = 8, 657 ± 227-fold) to one course of 13-cis RA. Limitations: The small number of patients with acne treated with 13-cis RA was a major limitation. Conclusion: Factors other than CYP26 activity may determine response to isotretinoin in acne.

AB - Background: The cytochrome P450 (CYP) enzyme CYP26 (retinoic acid [RA] 4-hydroxylase) initiates the catabolism of all-trans RA (tRA) and limits the effects of tRA. The CYP26 enzyme acts specifically on tRA, but not 13-cis RA (isotretinoin), a retinoid used to treat severe acne. However, 13-cis RA can isomerize to tRA, which can then be metabolized by CYP26. Objective: In healthy individuals, we assessed the variability of CYP26 enzymatic activity. We then investigated whether response to oral 13-cis RA among patients with acne correlates with variability in CYP26 expression. Methods: In healthy individuals, we isolated microsomal fractions from the epidermis of keratome biopsy specimens and measured CYP26 enzymatic activity in untreated skin and skin treated with tRA. Enzymatic activity was determined based on rate of formation of 4-hydroxy RA (pg/min/mg microsomal protein). Using real-time polymerase chain reaction we quantified CYP26 messenger RNA induction after tRA application in patients with acne who responded or did not respond to one course of 13-cis RA. Results: In normal-appearing skin (N = 118), CYP26 enzymatic activity was widely variable (1-180 pg/min/mg microsomal fraction; mean 42.7 ± 3.5). Furthermore, CYP26 enzymatic activity was inducible in a dose-dependent manner in normal-appearing skin after tRA application, but not correlated with age or sex (N = 29). In patients with acne, CYP26 messenger RNA induction after 0.1% tRA application did not differ (P > .05) between patients who responded (N = 8, 587 ± 325-fold) or did not respond (N = 8, 657 ± 227-fold) to one course of 13-cis RA. Limitations: The small number of patients with acne treated with 13-cis RA was a major limitation. Conclusion: Factors other than CYP26 activity may determine response to isotretinoin in acne.

KW - cytochrome

KW - isotretinoin

KW - retinoic acid 4-hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=67650108513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650108513&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2009.03.013

DO - 10.1016/j.jaad.2009.03.013

M3 - Article

C2 - 19525031

AN - SCOPUS:67650108513

VL - 61

SP - 252

EP - 258

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -